

Evidence Based Child and Adolescent Psychopharmacology

This tool has been developed to guide teams (inclusive of youth, family, educators and mental health practitioners) in determining appropriate psychopharmacological treatment. Teams should use this information to prioritize promising options. For specific details about these medications and their applications, see the most recent State of Hawaii DOH/CAMHD Evidence Based Services Committee Biennial Report at the following web site: <http://www.state.hi.us/doh/camhd/index.html>

| PROBLEM AREA | MEDICATION | SHORT-TERM EFFICACY | LONG-TERM EFFICACY | SHORT-TERM SAFETY | LONG-TERM SAFETY |
|-------------------------------------|-----------------------------|---------------------|--------------------|-------------------|------------------|
| Anxiety Disorders | Benzodiazepines | C | C | C | C |
| | SSRIs | C | C | C | C |
| Obsessive-Compulsive Disorder | SSRIs | A | C | A | C |
| ADHD | Stimulants | A | B | A | A |
| | TCAs | B | C | B | B |
| | Central Adrenergic Agonists | C | C | B | C |
| Aggression in Autism | Antipsychotics | B | C | C | B |
| Aggressive Conduct | Lithium | B | C | C | C |
| | Valproate and Carbamazepine | C | C | A | A |
| Bipolar Disorder | Lithium | B | C | B | C |
| | Valproate and Carbamazepine | C | C | A | A |
| Depression | SSRIs | B | C | A | C |
| | TCAs | C | C | B | B |
| Schizophrenia (psychotic disorders) | Antipsychotics | B | C | C | B |
| Tourettes | Antipsychotics | A | C | B | B |
| | Central Adrenergic Agonists | B | C | B | C |

Key:

SSRI = Selective Serotonin Reuptake Inhibitor

TCA = Tricyclic Antidepressant

A = Adequate data to inform prescribing practices. For efficacy and short-term safety: 2 \geq randomized controlled trials (RCT) in youth. For long-term safety: Epidemiological evidence and/or minimal adverse incident report to the Food and Drug Administration

B = For efficacy and short-term safety: 1 RCT in youth or mixed results from 2 \geq RCTs.

C = No controlled evidence